T细胞免疫反应载体疫苗在人类疾病预防和治疗中的应用

doi:10.12211/2096-8280.2023-071

合成生物学 ›› 2024, Vol. 5 ›› Issue (2): 294-309.DOI: 10.12211/2096-8280.2023-071

T细胞免疫反应载体疫苗在人类疾病预防和治疗中的应用

江莎莎¹, 王晨¹, 路冉², 刘俸君³, 李俊¹, 王斌¹^,³

^1.青岛大学基础医学院，病原生物学系，山东青岛 266000
^2.北京市朝阳区疾病预防控制中心，微生物检验科，北京 100021
^3.青岛大学基础医学院，特种医学系，山东青岛 266000

收稿日期:2023-10-07 修回日期:2024-03-12 出版日期:2024-04-30 发布日期:2024-04-28
通讯作者: 王斌
作者简介:江莎莎（1995—），女，博士研究生。研究方向为人巨细胞病毒疫苗的设计和研发。E-mail：15844207055@163.com
王晨（1998—），男，硕士研究生。研究方向为人巨细胞病毒疫苗的设计和研发。E-mail：13546694969@163.com
王斌（1962—），男，教授，博士生导师。研究方向为人类巨细胞病毒致神经损伤的分子机制和免疫学机制。E-mail：wangbin532@126.com
基金资助:
国家重点研发计划(2018YFA0900802);山东省重点研发计划(2019JZZY011009);青岛市自然科学基金(20-2-3-4-nsh)

Applications of vector vaccines developed through T-cell immune responses in preventing and treating human diseases

Shasha JIANG¹, Chen WANG¹, Ran LU², Fengjun LIU³, Jun LI¹, Bin WANG¹^,³

^1.Department of Pathogenic Biology，School of Basic Medicine，Qingdao University，Qingdao 266000，Shandong，China
^2.Microbiological Laboratory，Chaoyang District Center for Disease Control and Prevention，Beijing 100021，China
^3.Department of Special Medicine，School of Basic Medicine，Qingdao University，Qingdao 266000，Shandong，China

Received:2023-10-07 Revised:2024-03-12 Online:2024-04-30 Published:2024-04-28
Contact: Bin WANG

摘要/Abstract

摘要：

人类疾病，特别是传染病和癌症，对公共卫生安全和全球经济构成前所未有的挑战。预防和治疗性疫苗的开发是应对人类疾病的优先对策。本文综述了疫苗载体的免疫学原理、T细胞载体疫苗设计策略及疫苗研究进展，为新型疫苗的设计提供新的思路。T细胞可以在机体发生感染后分化成不同的效应T细胞群，它们可以起到清除病原体的作用，关于效应T细胞功能和机制的研究对于设计能够引发基于T细胞免疫的疫苗至关重要。目前很多病毒（例如HIV、HCMV感染）和肿瘤疫苗的研发都侧重于T细胞类疫苗，在所有疫苗种类中，激活T细胞免疫反应的载体疫苗具有显著优势。许多来源的载体，包括病毒载体、细菌载体和核酸载体，它们在抗原提呈能力、免疫原性和保护效力方面都有良好的表现。此外，还总结了T细胞载体疫苗设计的策略，包括确定适当的抗原提呈途径和载体递送途径、确保生物安全性、如何选择合适的疫苗的载体、各种载体疫苗的优缺点等，尤其是mRNA疫苗在应对新冠疫情中发挥了重要的作用。疫苗载体的技术进步将会加速新型疫苗的研发，并且能促进人们对突发公共卫生事件的应对。

关键词: T细胞, 疫苗载体, 免疫, 抗原提呈, 传染病, 肿瘤

Abstract:

Human diseases, especially infectious diseases and cancers, pose unprecedented challenges to public health and the global economy, making the development of preventive and therapeutic vaccines a top priority for addressing these challenges. Among all vaccines, vector vaccines that activate T cell immune responses have significant advantages. This article reviews the immunological principles of vector vaccines, strategies for designing T cell vector vaccines, and their research advances. T cells, upon infection, can differentiate into various effector T cell subsets that play a crucial role in clearing pathogens. Research on the functions and mechanisms of effector T cells is essential for designing vaccines that can elicit T cell-mediated immunity. Currently, the development of vaccines for many viruses such as HIV and HCMV as well as cancers focuses on T cell-based vaccines. Various vectors, including viral vectors, bacterial vectors, and nucleic acid vectors, exhibit excellent performance on antigen delivery capability, immunogenicity, and protective efficacy. In addition, this article summarizes strategies for designing T-cell vector vaccines, including identifying appropriate antigen presentation pathways and vector delivery routes, ensuring biological safety, selecting suitable vaccine vectors, and evaluating the advantages and disadvantages of various vector vaccines. Notably, mRNA vaccines have played a crucial role in addressing the challenges posed by the COVID-19 pandemic. Technological advancements in vector vaccines are expected to accelerate the development of novel vaccines and enhance preparedness for emerging public health events. This review provides insights for the design of vector vaccines that are both safe and efficient. With advancements in vector vaccine technology and the progress of various interdisciplinary approaches, the next generation of vaccine development will continue to drive the evolution of vaccinology. {L-End}

Key words: T cells, vaccine carrier, immunization, antigen presentation, infectious diseases, tumor

中图分类号:

Q819

江莎莎, 王晨, 路冉, 刘俸君, 李俊, 王斌. T细胞免疫反应载体疫苗在人类疾病预防和治疗中的应用[J]. 合成生物学, 2024, 5(2): 294-309.

Shasha JIANG, Chen WANG, Ran LU, Fengjun LIU, Jun LI, Bin WANG. Applications of vector vaccines developed through T-cell immune responses in preventing and treating human diseases[J]. Synthetic Biology Journal, 2024, 5(2): 294-309.

图/表 1

参考文献 139

1	CROTTY S. Follicular helper CD4 T cells (TFH)[J]. Annual Review of Immunology, 2011, 29: 621-663.
2	ZHU J F, YAMANE H, PAUL W E. Differentiation of effector CD4 T cell populations*[J]. Annual Review of Immunology, 2010, 28: 445-489.
3	SALLUSTO F, LANZAVECCHIA A, ARAKI K, et al. From vaccines to memory and back[J]. Immunity, 2010, 33(4): 451-463.
4	LEVIN M J, OXMAN M N, ZHANG J H, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine[J]. The Journal of Infectious Diseases, 2008, 197(6): 825-835.
5	MCELHANEY J E, XIE D X, HAGER W D, et al. T cell responses are better correlates of vaccine protection in the elderly[J]. Journal of Immunology, 2006, 176(10): 6333-6339.
6	PANTALEO G, KOUP R A. Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know[J]. Nature Medicine, 2004, 10(8): 806-810.
7	BUNDE T, KIRCHNER A, HOFFMEISTER B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells[J]. The Journal of Experimental Medicine, 2005, 201(7): 1031-1036.
8	HOFT D F. Tuberculosis vaccine development: goals, immunological design, and evaluation[J]. Lancet, 2008, 372(9633): 164-175.
9	REYES-SANDOVAL A, PEARSON F E, TODRYK S, et al. Potency assays for novel T-cell-inducing vaccines against malaria[J]. Current Opinion in Molecular Therapeutics, 2009, 11(1): 72-80.
10	REINA-CAMPOS M, SCHARPING N E, GOLDRATH A W. CD8⁺ T cell metabolism in infection and cancer[J]. Nature Reviews Immunology, 2021, 21(11): 718-738.
11	CHAPMAN N M, BOOTHBY M R, CHI H B. Metabolic coordination of T cell quiescence and activation[J]. Nature Reviews Immunology, 2020, 20(1): 55-70.
12	SADELAIN M, RIVIÈRE I, RIDDELL S. Therapeutic T cell engineering[J]. Nature, 2017, 545(7655): 423-431.
13	SUN L N, SU Y H, JIAO A J, et al. T cells in health and disease[J]. Signal Transduction and Targeted Therapy, 2023, 8(1): 235.
14	KUMAR B V, CONNORS T J, FARBER D L. Human T cell development, localization, and function throughout life[J]. Immunity, 2018, 48(2): 202-213.
15	CHEN L P, FLIES D B. Molecular mechanisms of T cell co-stimulation and co-inhibition[J]. Nature Reviews Immunology, 2013, 13(4): 227-242.
16	HENRY C J, ORNELLES D A, MITCHELL L M, et al. IL-12 produced by dendritic cells augments CD8⁺ T cell activation through the production of the chemokines CCL1 and CCL17[J]. Journal of Immunology, 2008, 181(12): 8576-8584.
17	DÍAZ-MONTERO C M, NAGGAR S EL, KHAMI A AL, et al. Priming of naive CD8⁺ T cells in the presence of IL-12 selectively enhances the survival of CD8⁺CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model[J]. Cancer Immunology, Immunotherapy, 2008, 57(4): 563-572.
18	RAMOS H J, DAVIS A M, COLE A G, et al. Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8⁺ effector versus central memory T-cell fates[J]. Blood, 2009, 113(22): 5516-5525.
19	REDEKER A, WELTEN S P, BAERT M R, et al. The quantity of autocrine IL-2 governs the expansion potential of CD8⁺ T cells[J]. Journal of Immunology, 2015, 195(10): 4792-4801.
20	GETT A V, HODGKIN P D. A cellular calculus for signal integration by T cells[J]. Nature Immunology, 2000, 1(3): 239-244.
21	BORST J, AHRENDS T, BĄBAŁA N, et al. CD4⁺ T cell help in cancer immunology and immunotherapy[J]. Nature Reviews Immunology, 2018, 18(10): 635-647.
22	RUTERBUSCH M, PRUNER K B, SHEHATA L, et al. In vivo CD4⁺ T cell differentiation and function: revisiting the Th1/Th2 paradigm[J]. Annual Review of Immunology, 2020, 38: 705-725.
23	MARTIN M D, BADOVINAC V P, GRIFFITH T S. CD4 T cell responses and the sepsis-induced immunoparalysis state[J]. Frontiers in Immunology, 2020, 11: 1364.
24	LIU M A. Gene-based vaccines: recent developments[J]. Current Opinion in Molecular Therapeutics, 2010, 12(1): 86-93.
25	ROBINSON H L, AMARA R R. T cell vaccines for microbial infections[J]. Nature Medicine, 2005, 11(4 ): S25-S32.
26	NIDETZ N F, MCGEE M C, TSE L V, et al. Adeno-associated viral vector-mediated immune responses: understanding barriers to gene delivery[J]. Pharmacology & Therapeutics, 2020, 207: 107453.
27	XU Z L, MIZUGUCHI H, SAKURAI F, et al. Approaches to improving the kinetics of adenovirus-delivered genes and gene products[J]. Advanced Drug Delivery Reviews, 2005, 57(5): 781-802.
28	MAYS L E, WILSON J M. The complex and evolving story of T cell activation to AAV vector-encoded transgene products[J]. Molecular Therapy, 2011, 19(1): 16-27.
29	HASANPOURGHADI M, NOVIKOV M, ERTL H C J. COVID-19 vaccines based on adenovirus vectors[J]. Trends in Biochemical Sciences, 2021, 46(5): 429-430.
30	KOGER-PEASE C, PERERA D J, NDAO M. Recent advances in the development of adenovirus-vectored vaccines for parasitic infections[J]. Pharmaceuticals, 2023, 16(3): 334.
31	LASARO M O, ERTL H C J. New insights on adenovirus as vaccine vectors[J]. Molecular Therapy, 2009, 17(8): 1333-1339.
32	ZHOU X Y, XIANG Z Q, ERTL H C J. Vaccine design: replication-defective adenovirus vectors[J]. Methods in Molecular Biology, 2016, 1404: 329-349.
33	MACNEIL K M, DODGE M J, EVANS A M, et al. Adenoviruses in medicine: innocuous pathogen, predator, or partner[J]. Trends in Molecular Medicine, 2023, 29(1): 4-19.
34	TATSIS N, ERTL H C J. Adenoviruses as vaccine vectors[J]. Molecular Therapy, 2004, 10(4): 616-629.
35	MIZUGUCHI H, KAY M A, HAYAKAWA T. Approaches for generating recombinant adenovirus vectors[J]. Advanced Drug Delivery Reviews, 2001, 52(3): 165-176.
36	KRATZER R F, KREPPEL F. Production, purification, and titration of first-generation adenovirus vectors[J]. Methods in Molecular Biology, 2017, 1654: 377-388.
37	KAMEN A, HENRY O. Development and optimization of an adenovirus production process[J]. The Journal of Gene Medicine, 2004, 6(): S184-S192.
38	CHAN J F, KOK K H, ZHU Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan[J]. Emerging Microbes & Infections, 2020, 9(1): 221-236.
39	张倩, 胡倩倩, 王富珍, 等. 腺病毒载体疫苗研发进展[J]. 中国疫苗和免疫, 2020, 26(4): 484-492.
	ZHANG Q, HU Q Q, WANG F Z, et al. Research and development of adenovirus vectored vaccines[J]. Chinese Journal of Vaccines and Immunization, 2020, 26(4): 484-492.
40	HALPERIN S A, YE L Y, MACKINNON-CAMERON D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial[J]. Lancet, 2022, 399(10321): 237-248.
41	PARRINO J, GRAHAM B S. Smallpox vaccines: past, present, and future[J]. The Journal of Allergy and Clinical Immunology, 2006, 118(6): 1320-1326.
42	MACKETT M, SMITH G L, MOSS B. Vaccinia virus: a selectable eukaryotic cloning and expression vector[J]. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79(23): 7415-7419.
43	PANICALI D, PAOLETTI E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus[J]. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79(16): 4927-4931.
44	PUISSANT B, COMBADIÈRE B. Keeping the memory of smallpox virus[J]. Cellular and Molecular Life Sciences, 2006, 63(19-20): 2249-2259.
45	MOSS B. Vaccinia virus: a tool for research and vaccine development[J]. Science, 1991, 252(5013): 1662-1667.
46	NORBURY C C, MALIDE D, GIBBS J S, et al. Visualizing priming of virus-specific CD8⁺ T cells by infected dendritic cells in vivo [J]. Nature Immunology, 2002, 3(3): 265-271.
47	VAN STIPDONK M J B, HARDENBERG G, BIJKER M S, et al. Dynamic programming of CD8⁺ T lymphocyte responses[J]. Nature Immunology, 2003, 4(4): 361-365.
48	GÓMEZ C E, PERDIGUERO B, GARCIA-ARRIAZA J, et al. Poxvirus vectors as HIV/AIDS vaccines in humans[J]. Human Vaccines & Immunotherapeutics, 2012, 8(9): 1192-1207.
49	SÁNCHEZ-SAMPEDRO L, PERDIGUERO B, MEJÍAS-PÉREZ E, et al. The evolution of poxvirus vaccines[J]. Viruses, 2015, 7(4): 1726-1803.
50	GUO Z S, LU B F, GUO Z B, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics[J]. Journal for Immunotherapy of Cancer, 2019, 7(1): 6.
51	SUTTER G, MOSS B. Nonreplicating vaccinia vector efficiently expresses recombinant genes[J]. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89(22): 10847-10851.
52	SUTER M, MEISINGER-HENSCHEL C, TZATZARIS M, et al. Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain[J]. Vaccine, 2009, 27(52): 7442-7450.
53	VON KREMPELHUBER A, VOLLMAR J, POKORNY R, et al. A randomized, double-blind, dose-finding phase Ⅱ study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE[J]. Vaccine, 2010, 28(5): 1209-1216.
54	PITTMAN P R, HAHN M, LEE H S, et al. Phase 3 efficacy trial of modified vaccinia Ankara as a vaccine against smallpox[J]. The New England Journal of Medicine, 2019, 381(20): 1897-1908.
55	MUNIER C M L, ANDERSEN C R, KELLEHER A D. HIV vaccines: progress to date[J]. Drugs, 2011, 71(4): 387-414.
56	COTTINGHAM M G, CARROLL M W. Recombinant MVA vaccines: dispelling the myths[J]. Vaccine, 2013, 31(39): 4247-4251.
57	ZHOU Y, SULLIVAN N J. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine[J]. Current Opinion in Immunology, 2015, 35: 131-136.
58	曾谷城. 埃博拉病毒研究进展[J]. 中山大学学报(医学科学版), 2015, 36(2): 161-166.
	ZENG G C. Progresses and problems in Ebola virus research[J]. Journal of Sun Yat-Sen University (Medical Sciences), 2015, 36(2): 161-166.
59	WU L H, ZHANG Z, GAO H N, et al. Open-label phase Ⅰclinical trial of Ad5-EBOV in Africans in China[J]. Human Vaccines & Immunotherapeutics, 2017, 13(9): 2078-2085.
60	MILLIGAN I D, GIBANI M M, SEWELL R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial[J]. JAMA, 2016, 315(15): 1610-1623.
61	LICHTY B D, POWER A T, STOJDL D F, et al. Vesicular stomatitis virus: re-inventing the bullet[J]. Trends in Molecular Medicine, 2004, 10(5): 210-216.
62	FRECHA C, LÉVY C, COSSET F L, et al. Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy[J]. Molecular Therapy, 2010, 18(10): 1748-1757.
63	SASSO E, D’ALISE A M, ZAMBRANO N, et al. New viral vectors for infectious diseases and cancer[J]. Seminars in Immunology, 2020, 50: 101430.
64	BARBER G N. VSV-tumor selective replication and protein translation[J]. Oncogene, 2005, 24(52): 7710-7719.
65	DHAMA K, KARTHIK K, KHANDIA R, et al. Advances in designing and developing vaccines, drugs, and therapies to counter Ebola virus[J]. Frontiers in Immunology, 2018, 9: 1803.
66	LI H Y, ZHAO C Y, ZHANG Y H, et al. Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays[J]. Emerging Microbes & Infections, 2020, 9(1): 2269-2277.
67	SCHNELL M J, BUONOCORE L, KRETZSCHMAR E, et al. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles[J]. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93(21): 11359-11365.
68	CLARKE D K, HENDRY R M, SINGH V, et al. Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: standardized template with key considerations for a risk/benefit assessment[J]. Vaccine, 2016, 34(51): 6597-6609.
69	GEISBERT T W, FELDMANN H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections[J]. The Journal of Infectious Diseases, 2011, 204(S3): S1075-S1081.
70	卢建博, 郑文铝, 余云舟, 等. 重组水疱性口炎病毒载体病毒包装体系的建立及优化[J]. 生物技术通讯, 2018, 29(2): 183-188.
	LU J B, ZHENG W L, YU Y Z, et al. Establishment and optimization of recombinant VSV packaging system[J]. Letters in Biotechnology, 2018, 29(2): 183-188.
71	MONATH T P, NICHOLS R, TUSSEY L, et al. Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: model for assessment of live vaccines with neurotropic potential[J]. PLoS Pathogens, 2022, 18(6): e1010658.
72	JOHNSON J E, NASAR F, COLEMAN J W, et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human Primates[J]. Virology, 2007, 360(1): 36-49.
73	LAI L L, DAVEY R, BECK A, et al. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick[J]. JAMA, 2015, 313(12): 1249-1255.
74	ROSE N F, MARX P A, LUCKAY A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants[J]. Cell, 2001, 106(5): 539-549.
75	GIRARD-GAGNEPAIN A, AMIRACHE F, COSTA C, et al. Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs[J]. Blood, 2014, 124(8): 1221-1231.
76	FELICIANO D, OTT C M, ESPINOSA-MEDINA I, et al. YAP1 nuclear efflux and transcriptional reprograming follow membrane diminution upon VSV-G-induced cell fusion[J]. Nature Communications, 2021, 12(1): 4502.
77	NIKOLIC J, BELOT L, RAUX H, et al. Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein[J]. Nature Communications, 2018, 9(1): 1029.
78	CASE J B, ROTHLAUF P W, CHEN R E, et al. Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice[J]. Cell Host & Microbe, 2020, 28(3): 465-474.e4.
79	SHEN W W, PATNAIK M M, RUIZ A, et al. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia[J]. Blood, 2016, 127(11): 1449-1458.
80	MOROZOV I, MONATH T P, MEEKINS D A, et al. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission[J]. Emerging Microbes & Infections, 2021, 10(1): 651-663.
81	ROEDIGER E K, KUGATHASAN K, ZHANG X Z, et al. Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine[J]. Molecular Therapy, 2008, 16(6): 1161-1169.
82	MARZI A, FELDMANN F, GEISBERT T W, et al. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses[J]. Emerging Infectious Diseases, 2015, 21(2): 305-307.
83	IMAZU S, NAKAGAWA S, NAKANISHI T, et al. A novel nonviral vector based on vesicular stomatitis virus[J]. Journal of Controlled Release, 2000, 68(2): 187-194.
84	CLARKE D K, COOPER D, EGAN M A, et al. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector[J]. Springer Seminars in Immunopathology, 2006, 28(3): 239-253.
85	WITKO S E, JOHNSON J E, KALYAN N K, et al. Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression[J]. Journal of Virological Methods, 2010, 164(1-2): 43-50.
86	FUCHS J, FRANK I, KOCHAR N, et al. First-in-human phase Ⅰ clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine[J]. Retrovirology, 2012, 9(2): P134.
87	FUCHS J D, FRANK I, ELIZAGA M L, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090)[J]. Open Forum Infectious Diseases, 2015, 2(3): ofv082.
88	WILSON S R, WILSON J H, BUONOCORE L, et al. Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity[J]. Comparative Medicine, 2008, 58(2): 129-139.
89	BRANDSMA J L, SHYLANKEVICH M, SU Y H, et al. Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus[J]. Journal of Virology, 2007, 81(11): 5749-5758.
90	BRIDLE B W, BOUDREAU J E, LICHTY B D, et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus[J]. Molecular Therapy, 2009, 17(10): 1814-1821.
91	HUANG H, WANG Y J, WHITE A P, et al. Salmonella expressing a T-cell epitope from Sendai virus are able to induce anti-infection immunity[J]. Journal of Medical Microbiology, 2009, 58(Pt 9): 1236-1242.
92	FENNELLY G J, KHAN S A, ABADI M A, et al. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector[J]. Journal of Immunology, 1999, 162(3): 1603-1610.
93	FERRARI G, KOSTYU D D, COX J, et al. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines[J]. AIDS Research and Human Retroviruses, 2000, 16(14): 1433-1443.
94	GAHAN M E, WEBSTER D E, WESSELINGH S L, et al. Bacterial antigen expression is an important component in inducing an immune response to orally administered Salmonella-delivered DNA vaccines[J]. PLoS One, 2009, 4(6): e6062.
95	ZHANG X L, JEZA V T, PAN Q. Salmonella typhi: from a human pathogen to a vaccine vector[J]. Cellular & Molecular Immunology, 2008, 5(2): 91-97.
96	MITAMURA T, HIGASHIYAMA S, TANIGUCHI N, et al. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity[J]. The Journal of Biological Chemistry, 1995, 270(3): 1015-1019.
97	BUZZI S, RUBBOLI D, BUZZI G, et al. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients[J]. Cancer Immunology, Immunotherapy, 2004, 53(11): 1041-1048.
98	SHINEFIELD H R. Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use[J]. Vaccine, 2010, 28(27): 4335-4339.
99	JIANG S S, NAN F L, ZHANG S Y, et al. CRM197-conjugated multi antigen dominant epitope for effective human cytomegalovirus vaccine development[J]. International Journal of Biological Macromolecules, 2023, 224: 79-93.
100	ZHANG S Y, NAN F L, JIANG S S, et al. CRM197-conjugated peptides vaccine of HCMV pp65 and gH induce maturation of DC and effective viral-specific T cell responses[J]. Virulence, 2023, 14(1): 2169488.
101	HOEBE K, JANSSEN E, BEUTLER B. The interface between innate and adaptive immunity[J]. Nature Immunology, 2004, 5(10): 971-974.
102	SCHOEN C, STRITZKER J, GOEBEL W, et al. Bacteria as DNA vaccine carriers for genetic immunization[J]. International Journal of Medical Microbiology, 2004, 294(5): 319-335.
103	DUNHAM S P. The application of nucleic acid vaccines in veterinary medicine[J]. Research in Veterinary Science, 2002, 73(1): 9-16.
104	DERTZBAUGH M T. Genetically engineered vaccines: an overview[J]. Plasmid, 1998, 39(2): 100-113.
105	MEKONNEN Z A, GRUBOR-BAUK B, MASAVULI M G, et al. Toward DNA-based T-cell mediated vaccines to target HIV-1 and hepatitis C virus: approaches to elicit localized immunity for protection[J]. Frontiers in Cellular and Infection Microbiology, 2019, 9: 91.
106	PAGLIARI S, DEMA B, SANCHEZ-MARTINEZ A, et al. DNA vaccines: history, molecular mechanisms and future perspectives[J]. Journal of Molecular Biology, 2023, 435(23): 168297.
107	TIRIVEEDHI V, TUCKER N, HERNDON J, et al. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer[J]. Clinical Cancer Research, 2014, 20(23): 5964-5975.
108	BRENNER S, JACOB F, MESELSON M. An unstable intermediate carrying information from genes to ribosomes for protein synthesis[J]. Nature, 1961, 190: 576-581.
109	XU S Q, YANG K P, LI R, et al. mRNA vaccine era-mechanisms, drug platform and clinical prospection[J]. International Journal of Molecular Sciences, 2020, 21(18): 6582.
110	WOLFF J A, MALONE R W, WILLIAMS P, et al. Direct gene transfer into mouse muscle in vivo [J]. Science, 1990, 247(4949 Pt 1): 1465-1468.
111	SHROFF R T, CHALASANI P, WEI R, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors[J]. Nature Medicine, 2021, 27(11): 2002-2011.
112	JACKSON L A, ANDERSON E J, ROUPHAEL N G, et al. An mRNA vaccine against SARS-CoV-2-preliminary report[J]. The New England Journal of Medicine, 2020, 383(20): 1920-1931.
113	HEMMI H, TAKEUCHI O, KAWAI T, et al. A Toll-like receptor recognizes bacterial DNA[J]. Nature, 2000, 408(6813): 740-745.
114	KARIKÓ K, BUCKSTEIN M, NI H P, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA[J]. Immunity, 2005, 23(2): 165-175.
115	PARDI N, HOGAN M J, PORTER F W, et al. mRNA vaccines - a new era in vaccinology[J]. Nature Reviews Drug Discovery, 2018, 17(4): 261-279.
116	FELDMAN R A, FUHR R, SMOLENOV I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials[J]. Vaccine, 2019, 37(25): 3326-3334.
117	JONG W, LEAL L, BUYZE J, et al. Therapeutic vaccine in chronically HIV-1-infected patients: a randomized, double-blind, placebo-controlled phase Ⅱa trial with HTI-TriMix[J]. Vaccines, 2019, 7(4): 209.
118	ZHANG N N, LI X F, DENG Y Q, et al. A thermostable mRNA vaccine against COVID-19[J]. Cell, 2020, 182(5): 1271-1283.e16.
119	RICHNER J M, HIMANSU S, DOWD K A, et al. Modified mRNA vaccines protect against Zika virus infection[J]. Cell, 2017, 168(6): 1114-1125.e10.
120	XUE T, STAVROPOULOS E, YANG M, et al. RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection[J]. Infection and Immunity, 2004, 72(11): 6324-6329.
121	PASTOR F, BERRAONDO P, ETXEBERRIA I, et al. An RNA toolbox for cancer immunotherapy[J]. Nature Reviews Drug Discovery, 2018, 17(10): 751-767.
122	TOMBÁCZ I, WEISSMAN D, PARDI N. Vaccination with messenger RNA: a promising alternative to DNA vaccination[J]. Methods in Molecular Biology, 2021, 2197: 13-31.
123	LINARES-FERNÁNDEZ S, LACROIX C, EXPOSITO J Y, et al. Tailoring mRNA vaccine to balance innate/adaptive immune response[J]. Trends in Molecular Medicine, 2020, 26(3): 311-323.
124	FAGHFURI E, POURFARZI F, FAGHFOURI A H, et al. Recent developments of RNA-based vaccines in cancer immunotherapy[J]. Expert Opinion on Biological Therapy, 2021, 21(2): 201-218.
125	VAN NUFFEL A M, WILGENHOF S, THIELEMANS K, et al. Overcoming HLA restriction in clinical trials: immune monitoring of mRNA-loaded DC therapy[J]. Oncoimmunology, 2012, 1(8): 1392-1394.
126	IAVARONE C, O’HAGAN D T, YU D, et al. Mechanism of action of mRNA-based vaccines[J]. Expert Review of Vaccines, 2017, 16(9): 871-881.
127	SAXENA M, VAN DER BURG S H, MELIEF C J M, et al. Therapeutic cancer vaccines[J]. Nature Reviews Cancer, 2021, 21(6): 360-378.
128	JIANG T, ZHOU C C, REN S X. Role of IL-2 in cancer immunotherapy[J]. Oncoimmunology, 2016, 5(6): e1163462.
129	BECK J D, REIDENBACH D, SALOMON N, et al. mRNA therapeutics in cancer immunotherapy[J]. Molecular Cancer, 2021, 20(1): 69.
130	SAHIN U, MUIK A, DERHOVANESSIAN E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses[J]. Nature, 2020, 586(7830): 594-599.
131	KRAMMER F. SARS-CoV-2 vaccines in development[J]. Nature, 2020, 586(7830): 516-527.
132	EBERHARDT C S, SIEGRIST C A. Is there a role for childhood vaccination against COVID-19?[J]. Pediatric Allergy and Immunology, 2021, 32(1): 9-16.
133	袁军鸿, 杨昭庆, 马绍辉. mRNA疫苗的研究进展[J]. 中国生物制品学杂志, 2022(6): 734-739.
	YUAN J H, YANG Z Q, MA S H. Progress in research on mRNA vaccines[J]. Chinese Journal of Biologicals, 2022(6): 734-739.
134	胡佳欣, 章晓联. mRNA疫苗的原理、研究现状和展望[J]. 武汉大学学报(医学版), 2023, 44(9): 1033-1045.
	HU J X, ZHANG X L. mRNA vaccines: principle, current status and perspectives[J]. Medical Journal of Wuhan University, 2023, 44(9): 1033-1045.
135	SELBY L I, CORTEZ-JUGO C M, SUCH G K, et al. Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles[J]. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 2017, 9(5): e1452.
136	CAGIGI A, LORÉ K. Immune responses induced by mRNA vaccination in mice, monkeys and humans[J]. Vaccines, 2021, 9(1): 61.
137	NATAMI M, GORGZADEH A, GHOLIPOUR A, et al. An overview on mRNA-based vaccines to prevent monkeypox infection[J]. Journal of Nanobiotechnology, 2024, 22(1): 86.
138	HOU F J, ZHANG Y T, LIU X H, et al. mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge[J]. Nature Communications, 2023, 14(1): 5925.
139	WANG H, YIN P, ZHENG T T, et al. Rational design of a ‘two-in-one’ immunogen DAM drives potent immune response against mpox virus[J]. Nature Immunology, 2024, 25(2): 307-315.

[1]	叶青, 秦成峰. “国际公共卫生紧急事件”下的mRNA疫苗研发[J]. 合成生物学, 2024, 5(2): 310-320.
[2]	王步森, 徐婧含, 高智强, 侯利华. 病毒载体疫苗研究进展[J]. 合成生物学, 2024, 5(2): 281-293.
[3]	方超, 黄卫人. 合成生物学在肿瘤疫苗设计中的应用进展[J]. 合成生物学, 2024, 5(2): 239-253.
[4]	谭子斌, 梁康, 陈有海. 合成生物学在基于微生物载体肿瘤疫苗设计中的应用[J]. 合成生物学, 2024, 5(2): 221-238.
[5]	涂辉阳, 韩为东, 张斌. 肿瘤新抗原疫苗的设计与优化策略[J]. 合成生物学, 2024, 5(2): 254-266.
[6]	马雪璟, 郭畅, 华兆琳, 侯百东. 合成生物技术助力纳米颗粒疫苗理性设计时代的到来[J]. 合成生物学, 2024, 5(2): 353-368.
[7]	孟倩, 尹聪, 黄卫人. 肿瘤类器官及其在合成生物学中的研究进展[J]. 合成生物学, 2024, 5(1): 191-201.
[8]	马孟丹, 尚梦宇, 刘宇辰. CRISPR-Cas9系统在肿瘤生物学中的应用及前景[J]. 合成生物学, 2023, 4(4): 703-719.
[9]	陈家文, 黄建东, 孙海涛. 工程菌在肿瘤治疗方面的应用进展[J]. 合成生物学, 2023, 4(4): 690-702.
[10]	谢君鸿, 何晶晶, 周鹏辉. 合成生物学与工程化T细胞治疗[J]. 合成生物学, 2023, 4(2): 373-393.
[11]	林思思, 潘超, 张一帆, 刘尽尧. 基于表面涂层益生菌的肿瘤抗原口服递送系统[J]. 合成生物学, 2022, 3(4): 810-820.
[12]	许仕琳, 许海燕. 双特异性抗体及纳米技术在肿瘤免疫治疗中的应用进展[J]. 合成生物学, 2022, 3(2): 352-368.
[13]	宋斐, 刘宇辰, 蔡志明, 黄卫人. 基于CRISPR/Cas工具的肿瘤基因线路构建及应用[J]. 合成生物学, 2022, 3(1): 53-65.

T细胞免疫反应载体疫苗在人类疾病预防和治疗中的应用

Applications of vector vaccines developed through T-cell immune responses in preventing and treating human diseases

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 139

相关文章 13

编辑推荐

Metrics

本文评价